November 4, 2025 — Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced its financial results for the three and nine months ending Sept. 30, 2025, and provided a business update.
Total revenue for the three and nine months ending September 30, 2025, reached $73.5 million and $205.9 million, respectively, marking an 8% and 17% increase from the same periods in 2024. Net product sales of LUPKYNIS were $70.6 million and $197.2 million for the same periods, up 27% and 24%, respectively. Net income was $31.6 million and $76.4 million, up 119% and 1677%, respectively, compared to the same periods in 2024. The company is increasing its full-year 2025 total revenue guidance to $275 million to $280 million and net product sales guidance to $265 million to $270 million.
As of September 30, 2025, Aurinia had cash, cash equivalents, restricted cash, and investments totaling $351.8 million. For the nine months ended September 30, 2025, the company repurchased 12.2 million of its common shares for $98.2 million.
Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.
Peter Greenleaf, President and Chief Executive Officer of Aurinia
